1571 related articles for article (PubMed ID: 33508232)
21. Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.
Valero C; Lee M; Hoen D; Zehir A; Berger MF; Seshan VE; Chan TA; Morris LGT
JAMA Oncol; 2021 May; 7(5):739-743. PubMed ID: 33599686
[TBL] [Abstract][Full Text] [Related]
22. Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy.
Pham TV; Boichard A; Goodman A; Riviere P; Yeerna H; Tamayo P; Kurzrock R
Mol Oncol; 2020 Aug; 14(8):1680-1694. PubMed ID: 32530570
[TBL] [Abstract][Full Text] [Related]
23. The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.
Zeng H; Tong F; Bin Y; Peng L; Gao X; Xia X; Yi X; Dong X
Front Immunol; 2022; 13():834142. PubMed ID: 35242138
[TBL] [Abstract][Full Text] [Related]
24. Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity.
Hong TH; Cha H; Shim JH; Lee B; Chung J; Lee C; Kim NKD; Choi YL; Hwang S; Lee Y; Park S; Jung HA; Kim JY; Park YH; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH; Park WY
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33077514
[TBL] [Abstract][Full Text] [Related]
25. Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival.
Wood MA; Weeder BR; David JK; Nellore A; Thompson RF
Genome Med; 2020 Mar; 12(1):33. PubMed ID: 32228719
[TBL] [Abstract][Full Text] [Related]
26. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.
Roh W; Chen PL; Reuben A; Spencer CN; Prieto PA; Miller JP; Gopalakrishnan V; Wang F; Cooper ZA; Reddy SM; Gumbs C; Little L; Chang Q; Chen WS; Wani K; De Macedo MP; Chen E; Austin-Breneman JL; Jiang H; Roszik J; Tetzlaff MT; Davies MA; Gershenwald JE; Tawbi H; Lazar AJ; Hwu P; Hwu WJ; Diab A; Glitza IC; Patel SP; Woodman SE; Amaria RN; Prieto VG; Hu J; Sharma P; Allison JP; Chin L; Zhang J; Wargo JA; Futreal PA
Sci Transl Med; 2017 Mar; 9(379):. PubMed ID: 28251903
[TBL] [Abstract][Full Text] [Related]
27. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
Linette GP; Becker-Hapak M; Skidmore ZL; Baroja ML; Xu C; Hundal J; Spencer DH; Fu W; Cummins C; Robnett M; Kaabinejadian S; Hildebrand WH; Magrini V; Demeter R; Krupnick AS; Griffith OL; Griffith M; Mardis ER; Carreno BM
Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23662-23670. PubMed ID: 31685621
[TBL] [Abstract][Full Text] [Related]
28. Measuring Tumor Mutational Burden Using Whole-Exome Sequencing.
Vilimas T
Methods Mol Biol; 2020; 2055():63-91. PubMed ID: 31502147
[TBL] [Abstract][Full Text] [Related]
29. Single-cell meta-analyses reveal responses of tumor-reactive CXCL13
Liu B; Zhang Y; Wang D; Hu X; Zhang Z
Nat Cancer; 2022 Sep; 3(9):1123-1136. PubMed ID: 36138134
[TBL] [Abstract][Full Text] [Related]
30. STING signalling compensates for low tumour mutation burden to drive anti-tumour immunity.
Tan J; Egelston CA; Guo W; Stark JM; Lee PP
EBioMedicine; 2024 Mar; 101():105035. PubMed ID: 38401418
[TBL] [Abstract][Full Text] [Related]
31. Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response.
Montesion M; Murugesan K; Jin DX; Sharaf R; Sanchez N; Guria A; Minker M; Li G; Fisher V; Sokol ES; Pavlick DC; Moore JA; Braly A; Singal G; Fabrizio D; Comment LA; Rizvi NA; Alexander BM; Frampton GM; Hegde PS; Albacker LA
Cancer Discov; 2021 Feb; 11(2):282-292. PubMed ID: 33127846
[TBL] [Abstract][Full Text] [Related]
32. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
Fehlings M; Jhunjhunwala S; Kowanetz M; O'Gorman WE; Hegde PS; Sumatoh H; Lee BH; Nardin A; Becht E; Flynn S; Ballinger M; Newell EW; Yadav M
J Immunother Cancer; 2019 Sep; 7(1):249. PubMed ID: 31511069
[TBL] [Abstract][Full Text] [Related]
33. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
34. Hepatobiliary Tumor Organoids Reveal HLA Class I Neoantigen Landscape and Antitumoral Activity of Neoantigen Peptide Enhanced with Immune Checkpoint Inhibitors.
Wang W; Yuan T; Ma L; Zhu Y; Bao J; Zhao X; Zhao Y; Zong Y; Zhang Y; Yang S; Qiu X; Shen S; Wu R; Wu T; Wang H; Gao D; Wang P; Chen L
Adv Sci (Weinh); 2022 Aug; 9(22):e2105810. PubMed ID: 35665491
[TBL] [Abstract][Full Text] [Related]
35.
Liu J; Lin J; Wang X; Zheng X; Gao X; Huang Y; Chen G; Xiong J; Lan B; Chen C; Si L; Chen Y
Front Immunol; 2022; 13():725679. PubMed ID: 35844619
[TBL] [Abstract][Full Text] [Related]
36. Applicability of Routine Targeted Next-generation Sequencing to Estimate Tumor Mutational Burden (TMB) in Patients Treated With Immune Checkpoint Inhibitor Therapy.
Pinato DJ; Urus H; Newsom-Davis T; Du Parcq P; Belessiotis K; Mapara L; Gupta N; Power D; Weir J; Wong CN; Ratnakumaran RP; Dominy K; Khorashad J; Bower M
J Immunother; 2020; 43(2):53-56. PubMed ID: 31567705
[TBL] [Abstract][Full Text] [Related]
37. Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer.
Liu L; Bai X; Wang J; Tang XR; Wu DH; Du SS; Du XJ; Zhang YW; Zhu HB; Fang Y; Guo ZQ; Zeng Q; Guo XJ; Liu Z; Dong ZY
Clin Cancer Res; 2019 Dec; 25(24):7413-7423. PubMed ID: 31515453
[TBL] [Abstract][Full Text] [Related]
38. A New Pipeline to Predict and Confirm Tumor Neoantigens Predict Better Response to Immune Checkpoint Blockade.
Lazdun Y; Si H; Creasy T; Ranade K; Higgs BW; Streicher K; Durham NM
Mol Cancer Res; 2021 Mar; 19(3):498-506. PubMed ID: 33257508
[TBL] [Abstract][Full Text] [Related]
39. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.
Yu Y; Zhang J; Ni L; Zhu Y; Yu H; Teng Y; Lin L; Xue Z; Xue X; Shen X; Song H; Su X; Sun W; Cai Z
Hum Vaccin Immunother; 2022 Dec; 18(1):1-11. PubMed ID: 33689574
[TBL] [Abstract][Full Text] [Related]
40. Tumor Mutation Burden and Checkpoint Immunotherapy Markers in NUT Midline Carcinoma.
He M; Chernock R; Zhou S; Gondim M; Dehner LP; Pfeifer JD
Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):495-500. PubMed ID: 31180909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]